{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:10:39Z","timestamp":1794629439496,"version":"4.9.1"},"reference-count":37,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>High-dose melphalan plus autologous stem cell transplantation (ASCT) is a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM), and adequate hematopoietic stem cell (HSC) collection is crucial to ensure hematologic recovery after ASCT. In this prospective, observational study we evaluated HSC mobilization with granulocyte colony-stimulating factor (G-CSF), cyclophosphamide, and \u2018on-demand\u2019 plerixafor (in patients with &lt;20\u00d7106 CD34+ cells\/L after at least 4 days of G-CSF or failing to collect \u22651\u00d7106 CD34+ cells\/kg after the first apheresis) in NDMM patients treated with novel agent-based induction therapy. The primary endpoint was the rate of poor mobilizers (patients collecting &lt;2\u00d7106 CD34+ cells\/kg or requiring plerixafor rescue to reach an adequate HSC harvest). Secondary endpoints included the rate of patients collecting \u22652\u00d7106 CD34+ cells\/kg after plerixafor administration and the identification of factors predicting mobilization failure or plerixafor need. Overall, 301 patients (median age 60 years) were enrolled. Two hundred and eighty-seven of 301 (95%) and 274 of 301 (93%) patients collected \u22652\u00d7106 and \u22654\u00d7106 CD34+ cells\/kg, respectively, with a median of 9.9\u00d7106 CD34+ cells\/kg collected. Poor mobilizers were 48 of 301 (16%): 34 of 301 (11%) required plerixafor rescue, and 14 of 301 (5%) failed HSC collection regardless of plerixafor. Thirty-four of 38 (90%) patients receiving plerixafor collected \u22652\u00d7106 CD34+ cells\/kg. Bone marrow plasmacytosis at diagnosis &gt;60% (odds ratio [OR]=4.14), lenalidomide use (OR=4.45), and grade 3-4 hematologic toxicities during induction (OR=3.53) were independently associated with a higher risk of mobilization failure or plerixafor need. Cyclophosphamide plus G-CSF and \u2018on-demand\u2019 plerixafor is an effective strategy in NDMM patients treated with novel agents, resulting in a high rate of HSC collection and high HSC yield (clinicaltrials gov. identifier: NCT03406091).<\/jats:p>","DOI":"10.3324\/haematol.2023.284023","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T02:31:18Z","timestamp":1700101878000},"page":"1525-1534","source":"Crossref","is-referenced-by-count":10,"title":["A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and \u2018on-demand\u2019 plerixafor in multiple myeloma patients treated with novel agents"],"prefix":"10.3324","volume":"109","author":[{"given":"Roberto","family":"Mina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velia","family":"Bongarzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Saccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bertuglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mengarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Curci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Massimo","family":"Lemoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelvio","family":"Ballanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Floris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cupelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Rota-Scalabrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Cangialosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Nozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Anaclerico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"60801","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2021; 32(3):309-322.","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"60802","doi-asserted-by":"crossref","unstructured":"Cavo M, Gay F, Beksac M. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalanprednisone, with or without bortezomib\u2013lenalidomide\u2013 dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/ HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020; 7(6):e456-e468.","DOI":"10.1016\/S2352-3026(20)30099-5"},{"key":"60803","doi-asserted-by":"crossref","unstructured":"Hari P, Pasquini MC, Stadtmauer EA. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol. 2020; 38(Suppl 15):8506.","DOI":"10.1200\/JCO.2020.38.15_suppl.8506"},{"key":"60804","doi-asserted-by":"crossref","unstructured":"Goldschmidt H, Baertsch MA, Schlenzka J. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2021; 35(4):1134-1144.","DOI":"10.1038\/s41375-020-0948-0"},{"key":"60805","doi-asserted-by":"crossref","unstructured":"Cook G, Ashcroft AJ, Cairns DA. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016; 3(7):e340-e351.","DOI":"10.1016\/S2352-3026(16)30049-7"},{"key":"60806","doi-asserted-by":"crossref","unstructured":"Giralt S, Stadtmauer EA, Harousseau JL. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009; 23(10):1904-1912.","DOI":"10.1038\/leu.2009.127"},{"key":"60807","doi-asserted-by":"crossref","unstructured":"Giralt S, Costa L, Schriber J. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014; 20(3):295-308.","DOI":"10.1016\/j.bbmt.2013.10.013"},{"key":"60808","doi-asserted-by":"crossref","unstructured":"Mohty M, Ho AD. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Exp Hematol. 2011; 39(7):723-729.","DOI":"10.1016\/j.exphem.2011.05.004"},{"key":"60809","doi-asserted-by":"crossref","unstructured":"DiPersio JF, Micallef IN, Stiff PJ. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2009; 27(28):4767-4773.","DOI":"10.1200\/JCO.2008.20.7209"},{"key":"60810","doi-asserted-by":"crossref","unstructured":"DiPersio JF, Stadtmauer EA, Nademanee A. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009; 113(23):5720-5726.","DOI":"10.1182\/blood-2008-08-174946"},{"key":"60811","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Kaufman JL, Laubach J. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136(8):936-945.","DOI":"10.1182\/blood.2020005288"},{"key":"60812","doi-asserted-by":"crossref","unstructured":"Hulin C, Offner F, Moreau P. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib\/ thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study. Haematologica. 2021; 106(8):2257-2260.","DOI":"10.3324\/haematol.2020.261842"},{"key":"60813","doi-asserted-by":"crossref","unstructured":"Gay F, Musto P, Rota-Scalabrini D. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021; 22(12):1705-1720.","DOI":"10.1016\/S1470-2045(21)00535-0"},{"key":"60814","doi-asserted-by":"crossref","unstructured":"Rosi\u00f1ol L, Hebraud B, Oriol A. Integrated analysis of bortezomib-lenalidomide-dexamethasone vs bortezomibthalidomide-dexamethasone in transplant-eligible newly diagnosed myeloma. Clin Lymphoma, Myeloma Leuk. 2019; 19(10):1-2.","DOI":"10.1016\/j.clml.2019.09.002"},{"key":"60815","doi-asserted-by":"crossref","unstructured":"Johnsrud A, Ladha A, Muffly L. Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide +\/- plerixafor versus granulocyte colony-stimulating factor +\/- plerixafor in the lenalidomide era. Transplant Cell Ther. 2021; 27(7):590.e1-590.e8.","DOI":"10.1016\/j.jtct.2021.04.016"},{"key":"60816","doi-asserted-by":"crossref","unstructured":"Musto P, Simeon V, Grossi A. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell\u2019Adulto Multiple Myeloma Working Party study. Stem Cell Res Ther. 2015; 6(1):64.","DOI":"10.1186\/s13287-015-0033-1"},{"key":"60817","doi-asserted-by":"crossref","unstructured":"Laurent V, Fronteau C, Antier C. Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant. 2021; 56(2):395-399.","DOI":"10.1038\/s41409-020-01033-8"},{"key":"60818","doi-asserted-by":"crossref","unstructured":"Chhabra S, Callander N, Watts NL. Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023; 29(3):174.e1-174.e10.","DOI":"10.1016\/j.jtct.2022.11.029"},{"key":"60819","doi-asserted-by":"crossref","unstructured":"Clark RE, Bell J, Clark JO. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. Blood Cancer J. 2014; 4(10):e255.","DOI":"10.1038\/bcj.2014.79"},{"key":"60820","doi-asserted-by":"crossref","unstructured":"Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts T V, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 2011; 46(1):64-69.","DOI":"10.1038\/bmt.2010.78"},{"key":"60821","doi-asserted-by":"crossref","unstructured":"Milone G, Martino M, Spadaro A. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol. 2014; 164(1):113-123.","DOI":"10.1111\/bjh.12606"},{"key":"60822","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016; 127(24):2955-2962.","DOI":"10.1182\/blood-2016-01-631200"},{"key":"60823","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"60824","unstructured":"R Core Team. R: a language and environment for statistical computing (Version 4.2.1) [software]. 2021."},{"key":"60825","doi-asserted-by":"crossref","unstructured":"Weisel K, Besemer B, Haenel M. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients with high-risk newly diagnosed multiple myeloma: planned interim analysis of the GMMG-Concept Trial. Blood. 2022; 140(Suppl 1):1836-1838.","DOI":"10.1182\/blood-2022-156309"},{"key":"60826","doi-asserted-by":"crossref","unstructured":"Alegre A, Tomas JF, Martinez-Chamorro C. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant. 1997; 20(3):211-217.","DOI":"10.1038\/sj.bmt.1700867"},{"key":"60827","doi-asserted-by":"crossref","unstructured":"Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009; 43(3):181-195.","DOI":"10.1038\/bmt.2008.410"},{"key":"60828","doi-asserted-by":"crossref","unstructured":"Pavone V, Gaudio F, Console G. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006; 37(8):719-724.","DOI":"10.1038\/sj.bmt.1705298"},{"key":"60829","doi-asserted-by":"crossref","unstructured":"Gertz MA, Wolf RC, Micallef INM, Gastineau DA. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant. 2010; 45(9):1396-1403.","DOI":"10.1038\/bmt.2009.370"},{"key":"60830","doi-asserted-by":"crossref","unstructured":"Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2008; 22(6):1280-1282.","DOI":"10.1038\/sj.leu.2405035"},{"key":"60831","doi-asserted-by":"crossref","unstructured":"D\u2019Addio A, Curti A, Worel N. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant. 2011; 46(3):356-363.","DOI":"10.1038\/bmt.2010.128"},{"key":"60832","doi-asserted-by":"crossref","unstructured":"Dugan MJ, Maziarz RT, Bensinger WI. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin\u2019s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant. 2010; 45(1):39-47.","DOI":"10.1038\/bmt.2009.119"},{"key":"60833","doi-asserted-by":"crossref","unstructured":"Milone G, Conticello C, Leotta S. Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: high effectiveness, low toxicity, and affordable cost. Leuk Res Rep. 2020; 14:100227.","DOI":"10.1016\/j.lrr.2020.100227"},{"key":"60834","doi-asserted-by":"crossref","unstructured":"Hamadani M, Kochuparambil ST, Osman S. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant. 2012; 18(7):1128-1135.","DOI":"10.1016\/j.bbmt.2012.01.005"},{"key":"60835","doi-asserted-by":"crossref","unstructured":"Kumar S, Dispenzieri A, Lacy MQ. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007; 21(9):2035-2042.","DOI":"10.1038\/sj.leu.2404801"},{"key":"60836","doi-asserted-by":"crossref","unstructured":"Costa LJ, Abbas J, Hogan KR. Growth factor plus preemptive (\u2018just-in-time\u2019) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant. 2012; 47(11):1403-1408.","DOI":"10.1038\/bmt.2012.60"},{"key":"60837","doi-asserted-by":"crossref","unstructured":"Lemonakis K, Tatting L, Lisak M. Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients. Haematologica. 2023; 108(2):610-614.","DOI":"10.3324\/haematol.2022.281610"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284023\/76284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284023\/76945","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11344\/76284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:14Z","timestamp":1794045914000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284023","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}